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Objective: In the United States, around 50% of all musculoskeletal injuries are soft tis-
sue injuries including ligaments and tendons. The objective of this study is to assess the
role of amnion-derived cellular cytokine solution (ACCS) in carboxy-methyl cellulose
(CMC) gel in the healing of Achilles tendon in a rat model, and to examine its effects
on mechanical properties and collagen content. Methods: Achilles tendons of Sprague-
Dawley rats were exposed and transected. The distal and proximal ends were injected
with either saline or ACCS in CMC, in a standardized fashion, and then sutured using a
Kessler technique. Tendons from both groups were collected at 1, 2, 4, 6, and 8 weeks
postoperatively and assessed for material properties. Collagen studies were performed,
including collagen content, collagen cross-linking, tendon hydration, and immunohisto-
chemistry. Tendons were also evaluated histologically for cross-sectional area. Results:
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Mechanical testing demonstrated that treatment with ACCS in CMC signiﬁcantly en-
hances breaking strength, ultimate tensile strength, yield strength, and Young’s modulus
in the tendon repair at early time points. In context, collagen content, as well as collagen
cross-linking,wasalsosigniﬁcantlyaffectedbythetreatment.Conclusion:Theapplica-
tion of ACCS in CMC has a positive effect on healing tendons by improving mechanical
properties at early time points. Previous studies on onetime application of ACCS (not
in CMC) did not show signiﬁcant improvement on tendon healing at any time point.
Therefore, the delivery in a slow release media like CMC seems to be essential for the
effects of ACCS demonstrated in this study.
Patient-induced and iatrogenic tendon injuries are common clinical problems.1 The esti-
mated incidence of tendinous and ligamentous injuries is 166.6/100,000 per year for males
and 52.1/100,000 per year for females.2,3 In the United States, around 50% of all muscu-
loskeletal injuries are soft tissue injuries including ligaments and tendons.4 More than 32
million traumatic and repetitive motion injuries to tendons and ligaments are recorded each
year,5 costing the United States an estimated $30 billion annually.6
Tendon is made up of dense regular connective tissue rich in collagen,7,8 is character-
ized by hypovascularity and hypocellularity,9 and often demonstrates poor outcomes after
repair.Tendonhealingpassesthroughthe3overlappingphases:inﬂammation,proliferation,
and the remodeling. During the inﬂammatory phase, macrophages release growth factors,
which induce the formation of extracellular matrix and ﬁbroblast proliferation.10 During
the proliferative phase, epitenon cells start to proliferate about 3 days after tendon injury.
There is migration and longitudinal deposition of the ﬁbroblasts in the superﬁcial layers
of the tendon.11 Neovascularization is evident 7 days after tendon repair with formation
of vascular channels extending into the repair site. There is also evidence of increased
cellularity in the endotenon while maximal proliferation still occurs in the epitenon.12
Degradation of the collagen ﬁbers is accompanied by deposition of newly synthesized ﬁne
collagen ﬁbers crossing the repair site.13 The remodeling phase of tendon tissue is a slow
process aiming at the formation of a functional scar that is believed to begin at the peak of
proliferation. Deposited type III collagen is slowly broken down by collagenases and re-
placedwithtypeIcollagen,allowingforgreatercross-linkingandhighertensilestrength.A
change from cellular to predominantly ﬁbrous tissue takes place in the ﬁrst few weeks.14-16
Diameter and cross-linking of the collagen ﬁbrils often remain inferior after the healing
process.17
Growth factors play a signiﬁcant role in mediating the tendon healing process, as in
other healing tissues.18 Vascular endothelial growth factor, platelet-derived growth factor,
and transforming growth factor were proven to have an increased expression following
injury and during different phases of tendon repair.19-21
Amnion-derivedcellslikestemcellspossesstheabilityofdifferentiatingintodifferent
cell lineages and produce cytokine growth factors,22-24 being beneﬁcial in the healing
process in various tissue healing models such as brain injury25,26 and acute wound failure
models.27
The supernatant of amnion-derived multipotent progenitor (AMP) cells, termed
amnion-derived cellular cytokine solution (ACCS), was found to contain physiologic levels
of cytokines important to healing processes.28 A possible positive effect of ACCS in wound
228KUECKELHAUS ET AL
healing was suggested in several prior studies.28-30 Two percent carboxymethyl cellulose
(CMC) gel is suggested to be the superior vehicle system for sustained delivery of growth
factors compared to biomatrix and to collagen.31
The hypothesis of this study was that tendon repair and the mechanical properties
after tendon injury could be improved by intratendinous injection of ACCS formulated in
a sustained release system.
MATERIALS AND METHODS
Cytokine solution preparation
Amnion-derived cellular cytokine solution (Stemnion Inc, Pittsburgh, Pennsylvania) was
formulated in a CMC gel. Brieﬂy, AMP cells isolated from human placenta were grown
to conﬂuence and the supernatant (ACCS) was harvested. Detailed analysis of the secreted
growth factor and cytokine proﬁle has previously been reported.28
Animals
A total of 104 female 10-week-old Sprague-Dawely rats (Charles River, Cambridge, Mas-
sachusetts) were housed 2 per cage, in 12/12 hours’ light/dark cycles and were given food
andwateradlibitum.Theywereallowedaperiodof3daysforacclimatization.TheHarvard
Medical Area standing committee on animals approved all animal procedures (Protocol no.
04794), and all institutional guidelines for the care and treatment of laboratory animals
were followed.
Experimental groups
Animals were randomly assigned to 2 different treatment groups: Saline (control) and
ACCS.Eachgroupwasfurtherdividedinto5subgroupsaccordingtopostoperativesurvival
time points: 1, 2, 4, 6, and 8 weeks. The 1-week subgroups (n = 6) were used exclusively
for histological studies, while animals in the subgroups pertaining to the other 4 time points
(n = 13-16) were either assigned to histological studies, or to mechanical testing. Out of
those, some specimens (n = 5) were used for collagen studies. An additional group (n =
10) was euthanized at time point 0 to test baseline tendon repair strength.
Surgical procedure
Rats were anesthetized using Ketamine (60 mg/kg IP; Putney, Inc, Portland, Maine) and
Xylazine (10 mg/kg IP; VEDCO, Inc, St Joseph, Missouri) and were maintained using
1% to 2% isoﬂurane (Hospira Inc, Lake Forest, Illinois) and oxygen. The right hind limb
was shaved, disinfected using successive alternate applications of 70% alcohol (prepared
from Surgipath Reagent Alcohol 100%, Leica, Richmond, Illinois) and 10% povidone
iodine (Purdue Products LP, Stamford, Connecticut) scrubs. A longitudinal incision was
made 1-cm proximal to the calcaneal insertion and sharp dissection was performed to
expose the Achilles tendon, which was transected at its midpoint. The midsubstance of
both the proximal and distal ends of the tendon was injected with either 100 μLo f0 . 9 %
sodium chloride solution (Hospira Inc, Lake Forest, Illinois) or ACCS in 100 μLC M C
gel. Ends were then approximated and repaired using the modiﬁed Kessler technique32,33
with 6-0 braided polyester sutures (Ethicon, Somerville, New Jersey). Skin was closed
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using5-0nylonmonoﬁlamentsutures(Ethicon),wrappedinPetroleumgauze(KENDALL,
Mansﬁeld, Massachusetts) and casted using a quick-drying casting tape (Scotchcast Plus,
3M) from toes to abdomen, achieving a 3-point stability (ankle-knee-hip).
Postoperative period
The animals were housed individually for a period of 1 week to allow immobilization of the
right hind limb. Three doses of postoperative analgesia using buprenorphine hydrochloride
(0.005 mg/kg SC, Reckitt BenckiserHealthcare,United Kingdom) were given immediately
aftersurgeryandinthecourseofthefollowing48hours.Ratswerecloselymonitoreddaily.
Cast removals were performed 1 week postoperatively to allow for weight bearing. Rats
were housed 2 per cage till their assigned euthanasia time, ranging from 1 to 8 weeks.
Euthanasia was performed using an overdose of isoﬂurane (10%). Achilles tendons
were dissected free of the extraneous soft tissue and harvested together with the calcaneal
bone and parts of the gastrocnemius and soleus muscle complex. The material testing
specimenswereimmediatelyfrozenat–80◦Cwhilespecimensforhistologyweredissected
in a similar fashion without the calcaneus. Three contralateral uninjured tendons from each
animal subgroup were harvested as controls.
Mechanical testing
On the day of evaluation, specimens were thawed to room temperature and prepared for
mechanical testing. The muscle was carefully separated from the proximal tendon by
blunt dissection to produce a fan of tendon ﬁbers34 that were then gripped by using a
large Pennington clamp (Johnson & Johnson, New Brunswick, New Jersey). The distal
end of the tendon was then gripped by using another Pennington clamp proximal to the
calcaneal insertion. The 2 Pennington clamps were then vertically secured in an Instron
5565 material testing system (Instron, Norwood, Massachusetts) by using pneumatic grips
with serrated jaw faces. Tendon width, radius, and length (distance between Pennington
clampends)wererecordedbyusingadigitalVerniercaliper.34 Thecross-sectionalareawas
calculated, assuming circular tendon geometry. Tendons were kept moist by using gauze
with saline throughout testing. Tendons were preconditioned for 3 cycles at 2% extension
immediately followed by a load-to-failure test at a speed of 6 mm/min.35 Loading force was
measured by using a 100-N load cell, and all data were collected with Blue-Hill 2 software
(Instron). Breaking strength (deﬁned as maximum force), stiffness (force required per unit
displacement), tensile strain (deﬁned as change in length over initial length mm/mm),
ultimate tensile strength (deﬁned as maximum stress or force per unit area), yield strength
(deﬁnedasmaximumstressinelasticregion),andYoungmodulus(ameasureofamaterial’s
resistance to elastic deformation) were obtained, and force versus displacement and stress
versus strain curves generated (Fig 1).
Histology
Six tendons from each treatment group at each time point were harvested for histology.
These tendons were immersed in 10% formalin for 24 hours and then rinsed in phos-
phate buffered saline. Tendons were then cut longitudinally for histological evaluation.
Parafﬁn-embedded sections were mounted onto slides and stained with H&E and Masson’s
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Trichrome using standard protocols. Sixty tendons, representing different treatment groups
at time points 2, 4, 6, and 8 weeks were used for tendon thickness measurements. An
average of 3 transverse measurements taken at the midpoint, proximal, and distal ends were
used to calculate tendon diameter and transverse cross-sectional area.
Figure 1. Examples of force versus displacement and stress versus strain curves. The results from
mechanical testing of tendons were used to generate force versus displacement and stress versus
strain curves, from which breaking strength, stiffness, yield strength, ultimate tensile strength, and
Young’s modulus could be extracted.
Fifteen longitudinal sections of rat Achilles tendon representing all treatment groups
at 1, 2, 4, 6, and 8 weeks were examined “blindly,” not knowing the treatment or the
time point for any tissue. Picrosirius red staining was utilized, which underpolarized light
“stains” collagen type I yellow-orange and collagen type III green.
Collagen studies
Chemicals
PyridinolinestandardswerepurchasedfromQuidel(SanDiego,California)andpentosidine
was purchased from Cayman Chemical Co. Hepatoﬂuorobutyric acid was from Fluka
(Sigma-Aldrich). Chloramine-T, perchloric acid, hydrochloric acid, and all other chemicals
were purchased from Sigma (St Louis, Missouri) and were of analytical grade or better.
Preparation of tissues
Following mechanical testing, rat tendons were sampled for hydration, total collagen con-
tent, and cross-link density from groups at 2, 4, 6, and 8 weeks. Hydration was determined
by wet weight/dry weight measurements of lyophilized tissue. Approximately 2 to 5 mg
samples were then hydrolyzed in 12M HCl in vacuo at 110◦C for 18 to 24 hours. An aliquot
of hydrolysate was taken for hydroxyproline analysis.
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Hydroxyproline assay
Hydroxyproline was measured using a 96-well microplate modiﬁcation of a traditional
colorimetric assay. Brieﬂy, samples were diluted in assay buffer. Chloramine-T reagent
was then added and allowed to react at room temperature for 20 minutes followed by the
additionofdimethylaminobenzaldehydereagentinperchloricacid.Afterheatingat60◦Cfor
15 minutes, absorbance was read at 550 nm. Sample concentrations were then determined
usingacommerciallyavailablehydroxyprolinestandard.Thevalueswereusedtodetermine
collagen content assuming 14% hydroxyproline per collagen molecule. Collagen content
was expressed as a percentage of dry weight.
Collagen cross-link analysis with high-performance liquid chromatography
The mature trifunctional cross-links pyridinoline (hydroxylysylpyridinoline) and de-
oxypyridinoline (lysylpyridinoline) as well as the nonreducible, difunctional, glycation-
associated, nonenzymatic cross-link pentosidine were measured on the basis of native
ﬂuorescence using an Agilent 1100 high-performance liquid chromatography system with
diode array detector and ﬂuorescence detector using Chemstation software (Rev A.10.02).
The chromatographic method consisted of an initial 20-minute isocratic run of 20 mM hep-
toﬂuorobutyricacidasanion-pairingagentwith20%methanol(MeOH)followedbya20%
to 40% MeOH gradient over the next 20 minutes. Pump ﬂow was 1 mL/min and column
temperature 25◦C. The ﬂuorescence detector was programmed to switch from pyridinoline
ﬂuorescence (ex295/em395) to pentosidine ﬂuorescence (ex328/em385) at 25 minutes to
match the retention times of the different cross-links. Commercially available standards
were used for cross-link quantitation and were expressed on a mole per mole basis with
collagen (MW˜300 kD). No prefractionation was necessary as the cross-link levels in the
rat tendon samples were found to be sufﬁcient in preliminary analyses.
Statistical analysis
Data were subjected to 2-way analysis of variance, with treatment and time as independent
factors. A Bonferroni post hoc test was used to determine statistical signiﬁcance. P < .05
was considered statistically signiﬁcant. All values are given as mean ± SD.
RESULTS
Material properties
A total of 104 rat Achilles tendons were transected, injected with saline or ACCS in CMC,
thensutured,andallowedtohealfor0,1,2,4,6,or8weeksbeforebeingharvested.Overall,
the surgical procedure was well tolerated, with a total of 3 rats (˜3%) lost postoperatively.
Breaking strength
At the 2-week time point, the ACCS in CMC-treated tendons showed signiﬁcantly higher
breaking strength compared to controls (Fig 2). Only at the 8-week time point, the controls
demonstrate higher breaking strength than the ACCS in CMC group.
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Stiffness
The tendons’ Stiffness increased over time but showed no signiﬁcant differences between
the study groups (Fig 2).
Ultimate tensile strength
The ACCS in CMC-treated tendons showed signiﬁcantly higher ultimate tensile strength
at weeks 2 and 4 compared to the saline-treated controls (Fig 2). At week 6, there was no
difference between study groups observed, whereas at week 8, the saline-treated tendons
showed signiﬁcantly higher ultimate tensile strength.
Yield strength
The yield strength was higher in ACCS in CMC-treated tendons at weeks 2, 4, and 6, the 4-
and6-weektimepointsbeingofstatisticalsigniﬁcance(Fig2).Atweek8,thesaline-treated
tendons showed signiﬁcantly higher yield strength.
Figure 2. Material properties of tendons. Graphs summarizing the material properties of tendons
treated with amnion-derived cellular cytokine solution (ACCS) and saline control 2, 4, 6, and 8
weeks after repair. UTS indicates ultimate tensile strength. aP > .05.
Young’s modulus
The ACCS-treated tendons demonstrated a signiﬁcantly higher Young’s modulus at week
4 than saline-treated tendons (Fig 2). Uninjured tendons were found to have a Young’s
modulus of 240 Pa.
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Table 1. Collagen I versus III content in tendons treated with ACCS or saline
Time point, wk Treatment Type I collagen, % Type III collagen, %
1 ACCS <33 >66
Saline <33 >66
2 ACCS 40-60 40-60
Saline 40-60 40-60
4 ACCS 40-60 40-60
Saline 40-60 40-60
6 ACCS 40-60 40-60
Saline >66 <33
8 ACCS >66 <33
Saline >66 <33
ACCS indicates amnion-derived cellular cytokine solution.
Histology and immunohistochemistry
The lesions presented in all sections by bright ﬁeld examination consisted of an irregularly
lineararrayofimmatureconnectivetissueineithertherepairphaseortheremodelingphase,
or perhaps both in different areas of individual sections. The slides were examined for the
proportion of collagen type I versus collagen type III. Because of the variation encountered
and subjective nature of this evaluation, samples were assigned to 1 of 3 groups:
1. More than 66% of the collagen (in the repair or remodeling zone) was type III
2. With variation, there was signiﬁcant amounts of both collagen type III and collagen
type I in the repair/remodeling zone.
3. Less than 33% of the collagen in the repair/remodeling zone was type III.
The results are presented in Table 1.
Collagen studies
As shown in Figure 3, tissue hydration was shown to decrease from approximately 70%
to 55% over the course of 8 weeks in all groups, with no signiﬁcant differences observed
between groups.
Itiswellknownthattotalcollagencontentrisesrapidlyduringthe“proliferativephase”
(day 4-14) and levels stabilize at 4 to 5 weeks during the early portion of the “maturation
phase.”AsshowninFigure3,by2weekspostinjury,totalcollagencontentlevelswere80%
and 93% of the levels observed at 6 weeks for controls and ACCS in CMC, respectively,
reﬂecting the fact that much of the collagen deposited into the healing wound bed has
already occurred at 2 weeks. As compared to controls, the rise in content occurred faster in
the ACCS in CMC group, with near maximal levels noted at 2 and 4 weeks. In this regard
and in comparison to controls, the collagen content in the ACCS in CMC group showed an
18% (2 weeks) and 21% (4 weeks) increase.
Regarding cross-link density, at 2 weeks, there was a statistically signiﬁcant increase
for the ACCS in CMC group over controls (P < .05) (Fig 3). A smaller difference was seen
for ACCS in CMC over controls at 4 and 6 weeks. By 8 weeks, the ACCS in CMC group
had stabilized and levels were noted to be lower than in controls. Almost identical levels of
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pyridinoline were observed in both groups at 6 weeks. Pentosidine was not detected in any
of the samples tested.
Figure 3. Graphs summarizing tendon collagen content, cross-linking, and hydration. A hydrox-
yprolineassaywasusedtodeterminethecollagencontentinthetendons,assuming14%hydroxypro-
line per collagen molecule. Collagen cross-link analysis was performed using native ﬂuorescence
and high-performance liquid chromatography. Tendon hydration was determined by wet weight/dry
weight measurements of lyophilized tissue. ACCS indicates amnion-derived cellular cytokine solu-
tion. ∗P > .05.
DISCUSSION
EarlierstudiesshowedthatthetreatmentoftransectedtendonswithAMPcellscanpositively
effect the mechanical properties of healing tendons.36 In this study, we examined the
biomechanicalpropertiesofratsAchillestendonsaftertransectionandapplicationofACCS
in a sustained-release formulation. The results obtained demonstrate signiﬁcant beneﬁcial
effects of ACCS in CMC at early time points of 2 and 4 weeks.
Breaking strength is deﬁned as the ability of a material to resist tension force to the
pointwhereitrupturesorbreaks.TheACCSinCMC-treatedtendonsshowedasigniﬁcantly
higher breaking strength than controls after 2 weeks. In the previous study by Philip et al,
no direct effect on breaking strength in the ACCS in saline group was demonstrated, but it
was shown that more tendons in the ACCS group had healed to the point where they could
be mechanically tested, suggesting an earlier improvement in healing than in the saline
group.
Theultimatetensilestrengthisthemaximumstressthatamaterialcanwithstandwhile
being stretched or pulled before failing or breaking. In this study, ACCS in CMC signiﬁ-
cantly enhanced the tendons ultimate tensile strength at week 2 and 4 but not thereafter.
Yieldstrengthisdeﬁnedasthemaximumstressamaterialcansustainbeforebeginning
to deform plastically. A trend toward improved yield strength in ACCS-treated tendons was
observed from week 2 and onward and this trend became statistically signiﬁcant at weeks
4 and 6.
The Young’s modulus measures the relative stiffness of a material. Excessive or too
little stiffness compared the one of a healthy tendon is not desirable. The ACCS-treated
tendonsdemonstratedasigniﬁcantlyhigherYoung’smodulusatweek4comparedtotendons
treated with saline.
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The higher collagen content and the signiﬁcantly higher cross-link density of ACCS-
treated tendons at early time points compared to the control may provide an explanation for
the improvement of mechanical properties. In previous studies, trifunctional pyridinoline
cross-links peaked at 4 to 6 weeks postwounding.37 Thereafter, the levels were variable and
slowly decline over the course of 6 months. Amnion-derived cellular cytokine solution may
have had a stabilizing effect on the healing wound, helping to advance the wound into a
more long-term remodeling phase at an earlier time.
This study has certain limitations. The retention volume and cytokine release pattern
was not studied in this experimental setup. However, in our previous study with ACCS in
saline as treatment group, the lack of signiﬁcant positive effects on tendon healing was
anticipated to be caused by the apparent effects of enzymatic degradation. The positive
results from the group with ACCS in CMC in this study suggest a sustained release of
the cytokines. Carboxymethyl cellulose has been reported as a carrier for sustained drug
release in the literature.38-40 In this context, a limitation of the study is that there is a saline
control as negative control but no CMC-only group as vehicle control.
The improved mechanical properties of ACCS in CMC-treated rat tendons at early
time points were demonstrated in this study. Signiﬁcant enhancements were observed in
breaking strength, ultimate tensile strength, yield strength, and Young’s modulus. This
could allow for higher loading at an earlier time, which has been shown to improve healing
outcomes. The lack of positive effects of ACCS in CMC at 8 weeks might be due to the
one time only application in the sustained-release media CMC. However, the early stages
of tendon healing are the critical time points for patients with tendon injuries.
Future studies should investigate if multiple applications of ACCS in CMC prolong
the positive effects on tendon healing.
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